Floatz logo

Pralatraxate

NK-Cell Lymphoma

New York Medical CollegeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the NK-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
New York Medical College
Phase 3BBB
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 3BB
CYCLOSPORIN A
Medical College of Wisconsin
Phase 3B
Equine Atg
Masonic Cancer Center, University of Minnesota
Phase 2B
Umbilical Cord Blood Mononuclear Cells
Masonic Cancer Center, University of Minnesota
Phase 2B

View all 26 →

Same molecule, other indications

Pralatraxate is also rated in:

aggressive NK-cell leukemiaDormant
C
Indicative ·
39 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →